• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一种熵安全锁控制丙型肝炎病毒进入和抗体耐药性。

An entropic safety catch controls hepatitis C virus entry and antibody resistance.

机构信息

Institute of Immunity and Transplantation, Division of Infection and Immunity, University College London, London, United Kingdom.

Institute of Structural and Molecular Biology, Birkbeck College, London, United Kingdom.

出版信息

Elife. 2022 Jul 7;11:e71854. doi: 10.7554/eLife.71854.

DOI:10.7554/eLife.71854
PMID:35796426
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9333995/
Abstract

E1 and E2 (E1E2), the fusion proteins of Hepatitis C Virus (HCV), are unlike that of any other virus yet described, and the detailed molecular mechanisms of HCV entry/fusion remain unknown. Hypervariable region-1 (HVR-1) of E2 is a putative intrinsically disordered protein tail. Here, we demonstrate that HVR-1 has an autoinhibitory function that suppresses the activity of E1E2 on free virions; this is dependent on its conformational entropy. Thus, HVR-1 is akin to a safety catch that prevents premature triggering of E1E2 activity. Crucially, this mechanism is turned off by host receptor interactions at the cell surface to allow entry. Mutations that reduce conformational entropy in HVR-1, or genetic deletion of HVR-1, turn off the safety catch to generate hyper-reactive HCV that exhibits enhanced virus entry but is thermally unstable and acutely sensitive to neutralising antibodies. Therefore, the HVR-1 safety catch controls the efficiency of virus entry and maintains resistance to neutralising antibodies. This discovery provides an explanation for the ability of HCV to persist in the face of continual immune assault and represents a novel regulatory mechanism that is likely to be found in other viral fusion machinery.

摘要

E1 和 E2(E1E2)是丙型肝炎病毒(HCV)的融合蛋白,与其他任何已描述的病毒都不同,HCV 进入/融合的详细分子机制仍不清楚。E2 的高变区-1(HVR-1)是一种假定的固有无序蛋白尾巴。在这里,我们证明 HVR-1 具有自动抑制功能,可抑制游离病毒粒子上的 E1E2 活性;这依赖于其构象熵。因此,HVR-1 类似于安全扣,可防止 E1E2 活动过早触发。至关重要的是,这种机制会被细胞表面的宿主受体相互作用关闭,以允许进入。降低 HVR-1 构象熵的突变,或 HVR-1 的遗传缺失,会关闭安全扣,从而产生超反应性 HCV,表现出增强的病毒进入能力,但热稳定性差且对中和抗体高度敏感。因此,HVR-1 安全扣控制病毒进入的效率,并维持对中和抗体的抗性。这一发现解释了 HCV 如何在持续的免疫攻击下持续存在,并代表了一种可能存在于其他病毒融合机制中的新型调节机制。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c0b7/9333995/4bf3968b2222/elife-71854-sa2-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c0b7/9333995/574297a4ba76/elife-71854-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c0b7/9333995/60706f72dfcf/elife-71854-fig1-figsupp1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c0b7/9333995/ac03ab0c31f7/elife-71854-fig1-figsupp2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c0b7/9333995/8bd9caaa9f6f/elife-71854-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c0b7/9333995/784f8c3afb16/elife-71854-fig2-figsupp1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c0b7/9333995/30c1effd813a/elife-71854-fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c0b7/9333995/ca94ff79c003/elife-71854-fig3-figsupp1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c0b7/9333995/c128ace3933d/elife-71854-fig3-figsupp2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c0b7/9333995/14430656aa83/elife-71854-fig3-figsupp3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c0b7/9333995/bb021f0f14da/elife-71854-fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c0b7/9333995/56b72eb688a9/elife-71854-fig4-figsupp1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c0b7/9333995/b45568f34b72/elife-71854-fig4-figsupp2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c0b7/9333995/bea7a6a09eaa/elife-71854-fig4-figsupp3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c0b7/9333995/8f0ab6d7ccc4/elife-71854-fig4-figsupp4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c0b7/9333995/bb3967fa92fb/elife-71854-fig4-figsupp5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c0b7/9333995/f8bc05c61543/elife-71854-fig5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c0b7/9333995/009dd2bf5ae5/elife-71854-fig6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c0b7/9333995/43af36f863ba/elife-71854-fig6-figsupp1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c0b7/9333995/4bf3968b2222/elife-71854-sa2-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c0b7/9333995/574297a4ba76/elife-71854-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c0b7/9333995/60706f72dfcf/elife-71854-fig1-figsupp1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c0b7/9333995/ac03ab0c31f7/elife-71854-fig1-figsupp2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c0b7/9333995/8bd9caaa9f6f/elife-71854-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c0b7/9333995/784f8c3afb16/elife-71854-fig2-figsupp1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c0b7/9333995/30c1effd813a/elife-71854-fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c0b7/9333995/ca94ff79c003/elife-71854-fig3-figsupp1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c0b7/9333995/c128ace3933d/elife-71854-fig3-figsupp2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c0b7/9333995/14430656aa83/elife-71854-fig3-figsupp3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c0b7/9333995/bb021f0f14da/elife-71854-fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c0b7/9333995/56b72eb688a9/elife-71854-fig4-figsupp1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c0b7/9333995/b45568f34b72/elife-71854-fig4-figsupp2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c0b7/9333995/bea7a6a09eaa/elife-71854-fig4-figsupp3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c0b7/9333995/8f0ab6d7ccc4/elife-71854-fig4-figsupp4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c0b7/9333995/bb3967fa92fb/elife-71854-fig4-figsupp5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c0b7/9333995/f8bc05c61543/elife-71854-fig5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c0b7/9333995/009dd2bf5ae5/elife-71854-fig6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c0b7/9333995/43af36f863ba/elife-71854-fig6-figsupp1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c0b7/9333995/4bf3968b2222/elife-71854-sa2-fig1.jpg

相似文献

1
An entropic safety catch controls hepatitis C virus entry and antibody resistance.一种熵安全锁控制丙型肝炎病毒进入和抗体耐药性。
Elife. 2022 Jul 7;11:e71854. doi: 10.7554/eLife.71854.
2
Flexibility and intrinsic disorder are conserved features of hepatitis C virus E2 glycoprotein.丙型肝炎病毒 E2 糖蛋白具有柔韧性和固有无序性的特征。
PLoS Comput Biol. 2020 Feb 28;16(2):e1007710. doi: 10.1371/journal.pcbi.1007710. eCollection 2020 Feb.
3
Critical interaction between E1 and E2 glycoproteins determines binding and fusion properties of hepatitis C virus during cell entry.E1 和 E2 糖蛋白之间的关键相互作用决定了丙型肝炎病毒在细胞进入过程中的结合和融合特性。
Hepatology. 2014 Mar;59(3):776-88. doi: 10.1002/hep.26733. Epub 2014 Jan 28.
4
Identification of conserved residues in hepatitis C virus envelope glycoprotein E2 that modulate virus dependence on CD81 and SRB1 entry factors.丙型肝炎病毒包膜糖蛋白E2中调节病毒对CD81和SRB1进入因子依赖性的保守残基的鉴定。
J Virol. 2014 Sep;88(18):10584-97. doi: 10.1128/JVI.01402-14. Epub 2014 Jul 2.
5
Identification of Novel Functions for Hepatitis C Virus Envelope Glycoprotein E1 in Virus Entry and Assembly.丙型肝炎病毒包膜糖蛋白E1在病毒进入和组装中的新功能鉴定
J Virol. 2017 Mar 29;91(8). doi: 10.1128/JVI.00048-17. Print 2017 Apr 15.
6
Functional expression and characterization of the envelope glycoprotein E1E2 heterodimer of hepatitis C virus.丙型肝炎病毒包膜糖蛋白 E1E2 异二聚体的功能表达和特性。
PLoS Pathog. 2019 May 22;15(5):e1007759. doi: 10.1371/journal.ppat.1007759. eCollection 2019 May.
7
Functional Study of the C-Terminal Part of the Hepatitis C Virus E1 Ectodomain.丙型肝炎病毒 E1 外域 C 末端部分的功能研究。
J Virol. 2018 Sep 26;92(20). doi: 10.1128/JVI.00939-18. Print 2018 Oct 15.
8
A Diverse Panel of Hepatitis C Virus Glycoproteins for Use in Vaccine Research Reveals Extremes of Monoclonal Antibody Neutralization Resistance.用于疫苗研究的多种丙型肝炎病毒糖蛋白组合揭示了单克隆抗体中和抗性的极端情况。
J Virol. 2015 Dec 23;90(7):3288-301. doi: 10.1128/JVI.02700-15.
9
Fine mapping of murine antibody responses to immunization with a novel soluble form of hepatitis C virus envelope glycoprotein complex.对新型可溶性丙型肝炎病毒包膜糖蛋白复合物免疫接种的小鼠抗体反应进行精细定位。
J Virol. 2014 Sep;88(18):10459-71. doi: 10.1128/JVI.01584-14. Epub 2014 Jun 25.
10
Glycan Shielding and Modulation of Hepatitis C Virus Neutralizing Antibodies.糖基掩蔽与丙型肝炎病毒中和抗体的调节。
Front Immunol. 2018 Apr 27;9:910. doi: 10.3389/fimmu.2018.00910. eCollection 2018.

引用本文的文献

1
Hepatitis C Virus E1E2 Structure, Diversity, and Implications for Vaccine Development.丙型肝炎病毒 E1E2 结构、多样性及其对疫苗开发的影响。
Viruses. 2024 May 18;16(5):803. doi: 10.3390/v16050803.
2
Viral Membrane Fusion: A Dance Between Proteins and Lipids.病毒膜融合:蛋白质与脂质的共舞。
Annu Rev Virol. 2023 Sep 29;10(1):139-161. doi: 10.1146/annurev-virology-111821-093413.
3
Prospects for developing an Hepatitis C virus E1E2-based nanoparticle vaccine.开发基于丙型肝炎病毒 E1E2 的纳米颗粒疫苗的前景。

本文引用的文献

1
Structural insights into hepatitis C virus receptor binding and entry.丙型肝炎病毒受体结合和进入的结构见解。
Nature. 2021 Oct;598(7881):521-525. doi: 10.1038/s41586-021-03913-5. Epub 2021 Sep 15.
2
Recurrent emergence of SARS-CoV-2 spike deletion H69/V70 and its role in the Alpha variant B.1.1.7.SARS-CoV-2 刺突缺失 H69/V70 的反复出现及其在 Alpha 变异株 B.1.1.7 中的作用。
Cell Rep. 2021 Jun 29;35(13):109292. doi: 10.1016/j.celrep.2021.109292. Epub 2021 Jun 8.
3
Design of a native-like secreted form of the hepatitis C virus E1E2 heterodimer.
Rev Med Virol. 2023 Sep;33(5):e2474. doi: 10.1002/rmv.2474. Epub 2023 Aug 11.
4
Hepatitis C virus hypervariable region 1 antibodies interrupt E2-SR-B1 interaction to suppress viral infection.丙型肝炎病毒高变区1抗体阻断E2-SR-B1相互作用以抑制病毒感染。
iScience. 2023 Mar 16;26(4):106421. doi: 10.1016/j.isci.2023.106421. eCollection 2023 Apr 21.
5
Regions of hepatitis C virus E2 required for membrane association.丙型肝炎病毒 E2 用于膜结合所需的区域。
Nat Commun. 2023 Jan 26;14(1):433. doi: 10.1038/s41467-023-36183-y.
6
Induction of cross-neutralizing antibodies by a permuted hepatitis C virus glycoprotein nanoparticle vaccine candidate.一种经重排的丙型肝炎病毒糖蛋白纳米颗粒疫苗候选物诱导交叉中和抗体。
Nat Commun. 2022 Nov 25;13(1):7271. doi: 10.1038/s41467-022-34961-8.
7
In vitro adaptation and characterization of attenuated hypervariable region 1 swap chimeras of hepatitis C virus.在体外适应和特征分析丙型肝炎病毒高度变异性区域 1 交换嵌合体的减毒株。
PLoS Pathog. 2021 Jul 19;17(7):e1009720. doi: 10.1371/journal.ppat.1009720. eCollection 2021 Jul.
设计一种类似天然的丙型肝炎病毒 E1E2 异二聚体的分泌形式。
Proc Natl Acad Sci U S A. 2021 Jan 19;118(3). doi: 10.1073/pnas.2015149118.
4
Technical Validation of a Hepatitis C Virus Whole Genome Sequencing Assay for Detection of Genotype and Antiviral Resistance in the Clinical Pathway.用于临床路径中丙型肝炎病毒基因型检测及抗病毒耐药性检测的全基因组测序分析方法的技术验证
Front Microbiol. 2020 Oct 9;11:576572. doi: 10.3389/fmicb.2020.576572. eCollection 2020.
5
Optimized cell systems for the investigation of hepatitis C virus E1E2 glycoproteins.优化的细胞系统用于丙型肝炎病毒 E1E2 糖蛋白的研究。
J Gen Virol. 2021 Jan;102(1). doi: 10.1099/jgv.0.001512.
6
Global and local envelope protein dynamics of hepatitis C virus determine broad antibody sensitivity.丙型肝炎病毒的全球和局部包膜蛋白动力学决定了广泛的抗体敏感性。
Sci Adv. 2020 Aug 26;6(35):eabb5938. doi: 10.1126/sciadv.abb5938. eCollection 2020 Aug.
7
Fluoxazolevir inhibits hepatitis C virus infection in humanized chimeric mice by blocking viral membrane fusion.氟康唑通过阻断病毒膜融合抑制人源嵌合小鼠中的丙型肝炎病毒感染。
Nat Microbiol. 2020 Dec;5(12):1532-1541. doi: 10.1038/s41564-020-0781-2. Epub 2020 Aug 31.
8
An alternate conformation of HCV E2 neutralizing face as an additional vaccine target.HCV E2 中和面的另一种构象作为附加疫苗靶点。
Sci Adv. 2020 Jul 24;6(30):eabb5642. doi: 10.1126/sciadv.abb5642. eCollection 2020 Jul.
9
Virus and eukaryote fusogen superfamilies.病毒和真核生物融合超家族。
Curr Biol. 2020 Jul 6;30(13):R750-R754. doi: 10.1016/j.cub.2020.05.029.
10
Chlorcyclizine Inhibits Viral Fusion of Hepatitis C Virus Entry by Directly Targeting HCV Envelope Glycoprotein 1.氯环利嗪通过直接靶向丙型肝炎病毒包膜糖蛋白1来抑制丙型肝炎病毒进入的病毒融合。
Cell Chem Biol. 2020 Jul 16;27(7):780-792.e5. doi: 10.1016/j.chembiol.2020.04.006. Epub 2020 May 7.